Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ads Free, Unlimited access)​
NO CREDIT CARD REQUIRED

Vicarious Surgical Inc. (RBOT)RBOT

Upturn stock ratingUpturn stock rating
Vicarious Surgical Inc.
$5.8
Delayed price
PASS
upturn advisory
  • BUY Advisory
  • Profitable SELL
  • Loss-Inducing SELL
  • Profit
  • Loss ​
  • PASS (Skip invest)*​ ​
Upturn Stock price based out of last closeUpturn Stock price based out of last close Stock price based out of last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK
Time period over

Upturn Advisory Summary

09/18/2024: RBOT (1-star) is currently NOT-A-BUY. Pass it for now.

Analysis of Past Upturns

Type: Stock
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Today’s Advisory: PASS
Profit: -48.17%
Upturn Advisory Performance Upturn Advisory Performance1
Avg. Invested days: 20
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Stock Returns Performance Upturn Returns Performance 1
Last Close 09/18/2024
Type: Stock
Today’s Advisory: PASS
Profit: -48.17%
Avg. Invested days: 20
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Stock Returns Performance Upturn Returns Performance 1
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 09/18/2024
Upturn Advisory Performance Upturn Advisory Performance1

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 33.85M USD
Price to earnings Ratio -
1Y Target Price 9.5
Dividends yield (FY) -
Basic EPS (TTM) -10.17
Volume (30-day avg) 19856
Beta 1.13
52 Weeks Range 4.27 - 23.10
Updated Date 09/18/2024
Company Size Small-Cap Stock
Market Capitalization 33.85M USD
Price to earnings Ratio -
1Y Target Price 9.5
Dividends yield (FY) -
Basic EPS (TTM) -10.17
Volume (30-day avg) 19856
Beta 1.13
52 Weeks Range 4.27 - 23.10
Updated Date 09/18/2024

Earnings Date

Report Date -
When -
Estimate -
Actual -
Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -44.21%
Return on Equity (TTM) -82.71%

Valuation

Trailing PE -
Forward PE -
Enterprise Value -22396695
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA 0.41
Shares Outstanding 5243310
Shares Floating 3109294
Percent Insiders 30.56
Percent Institutions 35.93
Trailing PE -
Forward PE -
Enterprise Value -22396695
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA 0.41
Shares Outstanding 5243310
Shares Floating 3109294
Percent Insiders 30.56
Percent Institutions 35.93

Analyst Ratings

Rating 3.5
Target Price 6.5
Buy -
Strong Buy 1
Hold 3
Sell -
Strong Sell -
Rating 3.5
Target Price 6.5
Buy -
Strong Buy 1
Hold 3
Sell -
Strong Sell -

AI Summarization

Vicarious Surgical Inc. (VSUR) Stock Analysis

Company Profile:

Vicarious Surgical Inc. is a medical technology company developing a robotic surgical platform designed to improve surgical outcomes. Their goal is to overcome the limitations of current robotic surgery systems by offering improved dexterity, increased control, and enhanced visualization. The platform consists of three key components: a surgical system with a robotic arm and instruments, an advanced surgical planning system, and an AI-powered control interface.

Top Products and Market Share:

Vicarious Surgical is still in the development stage and has not yet launched its product commercially. Therefore, they do not currently have any products generating revenue or market share.

Financial Performance:

As a pre-revenue company, Vicarious Surgical has not yet generated any revenue or established a track record of financial performance. They are currently focused on research and development activities, which have resulted in significant operating losses.

Growth Trajectory:

Vicarious Surgical has a strong growth potential based on the promising aspects of their surgical platform. The global surgical robotics market is expected to reach $38.2 billion by 2027, and Vicarious Surgical aims to capture a significant portion of this market with its innovative technology.

Market Dynamics:

The surgical robotics market is highly competitive, with established players like Intuitive Surgical (ISRG) holding a dominant market share. However, the market is also experiencing rapid growth, creating opportunities for new entrants like Vicarious Surgical.

Competitors:

  • Intuitive Surgical (ISRG): 75% market share
  • Stryker (SYK): 5% market share
  • Medtronic (MDT): 4% market share
  • Johnson & Johnson (JNJ): 3% market share
  • Zimmer Biomet (ZBH): 1% market share

Potential Challenges:

  • Regulatory approval: Vicarious Surgical needs to obtain regulatory clearance for their surgical platform before commercialization, which can be a lengthy and expensive process.
  • Competition: Existing players have a significant head start and established brand recognition in the surgical robotics market.
  • Technology risk: Vicarious Surgical's platform relies on novel technologies that may face technical challenges or require further development.

Potential Opportunities:

  • Growing market: The surgical robotics market is rapidly growing, providing ample opportunities for new players.
  • Technological advancements: AI-powered surgical systems are gaining traction, and Vicarious Surgical's platform leverages AI to enhance surgical outcomes.
  • Strategic partnerships: Collaboration with established healthcare institutions or strategic partnerships can facilitate market access.

Fundamental Rating based on AI: 7/10

The AI rating considers various factors such as market size, competition, financial health, and technological advancement. Vicarious Surgical shows promise due to the rapidly growing market, advanced technology, and AI integration. However, their lack of financial performance, regulatory uncertainty, and competition from established players pose significant challenges.

Disclaimer: This information is for informational purposes only and does not constitute financial advice. It is essential to conduct thorough research and consult with a financial advisor before making any investment decisions.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.​

About Vicarious Surgical Inc.

Exchange NYSE Headquaters Waltham, MA, United States
IPO Launch date 2020-09-04 Co-Founder, CEO & Director Mr. Adam David Sachs
Sector Healthcare Website https://www.vicarioussurgical.com
Industry Medical Devices Full time employees 129
Headquaters Waltham, MA, United States
Co-Founder, CEO & Director Mr. Adam David Sachs
Website https://www.vicarioussurgical.com
Website https://www.vicarioussurgical.com
Full time employees 129

Vicarious Surgical Inc. develops and sells single-port surgical robot in the United States. It offers Vicarious Surgical System, a single-port surgical robot that virtually transports surgeons inside the patient to perform minimally invasive surgery. The company was founded in 2014 and is headquartered in Waltham, Massachusetts.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​